StreetAlpha.app
Home › Stocks › LXRX

Lexicon Pharmaceuticals, Inc. (LXRX)

Healthcare
$1.53
▼ −8.38%
LAST CLOSE · NOV 20

Lexicon Pharmaceuticals develops drug candidates and sells INPEFA, a heart failure treatment, from The Woodlands, Texas. It last closed at $1.53 on Nov 20, down 8.38% on the day. The next earnings report for LXRX is expected around Thu, Jan 28, 2027, after the close. For the quarter ended Sep 2026, LXRX reported EPS of -$0.03 on revenue of $11.3M, with revenue down 20.7% from a year ago. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months LXRX insiders bought $2.8M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is LXRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LXRX.

Key Stats

Last 12 months
Results
Revenue
$38.5M
−45.6% vs a year ago
Net income
−$62.4M
−161.8% margin
EPS (diluted)
−$0.15
Gross margin
98.9%
$38.1M gross profit
Valuation
Market cap
$681.2M
445.2M shares
P/E
–
No P/E while losing money
Price to sales
17.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$44.1M
At Sep 30
Debt
$51.9M
At Sep 30
Shareholder equity
$163.8M
Shares outstanding
445.2M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $298K$298KFY2021FY2022: $139K$139KFY2022FY2023: $1.2M$1.2MFY2023FY2024: $31.1M$31.1MFY2024FY2025: $49.8M$49.8MFY2025

From LXRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 28
Estimated date · After the close
Reported EPS
-$0.03
Quarter ended Sep 2026
Year ago EPS
-$0.04
Same quarter last year
Revenue
$11.3M
−20.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.07Mar '25Jun 2025: $0.01Jun '25Sep 2025: -$0.04Sep '25Dec 2025: -$0.04Dec '25Mar 2026: $0.00Mar '26Jun 2026: -$0.07Jun '26Sep 2026: -$0.03Sep '26Latest -$0.03
Revenue by quarter
Dec 2024: $26.6MDec '24Mar 2025: $1.3MMar '25Jun 2025: $28.9MJun '25Sep 2025: $14.2MSep '25Dec 2025: $5.5MDec '25Mar 2026: $21.1MMar '26Jun 2026: $692,000Jun '26Sep 2026: $11.3MSep '26Latest $11.3M
How LXRX moved after its last 8 reports
Average move the session after a report ±8.3%
Nov 5, 2026Time not announced+8.8%
Aug 6, 2026Time not announced−3.7%
May 7, 2026Time not announced+5.0%
Mar 5, 2026Time not announced+0.6%
Jan 29, 2026After the close−19.4%
Nov 6, 2025Time not announced+3.6%
Aug 6, 2025Time not announced+9.5%
May 13, 2025After the close−15.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LXRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LXRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LXRX

Technical Analysis

LXRX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 7% below its 20 day and 13% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $1.43, and the nearest resistance the Pivot at $1.57.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.5%/day
Key levels
$2.6852 week high+75.2%
$2.01100 day average+31.4%
$1.90200 day average+24.2%
$1.7350 day average+13.1%
$1.68Swing high (Oct 16)+9.8%
$1.66Pivot R1+8.5%
$1.6320 day average+6.5%
$1.57Pivot+2.6%
$1.53Last close
$1.43Pivot S1−6.5%
$1.38Swing low (Oct 30)−9.8%
$1.1052 week low−28.1%
Indicators
RSI (14)38.74Weak, oversold below 30Neutral
MACD0.00Below its signal lineBearish
Stochastic40.8Middle of its rangeNeutral
ADX (14)27.9Trending down
Williams %R-83.0Oversold below −80, overbought above −20Oversold
CCI (20)-31.0Oversold below −100, overbought above 100Neutral
Rate of change−14.0%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LXRX

What happened before

See how LXRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LXRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LXRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LXRXHow many large options trades hit LXRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

LXRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼58 buying vs 77 selling
  • ▲Held by funds +1.1 pts
  • ▲Funds holding +7
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding157150+4.7%
In funds' top 10110.0%
Held by funds83.0%81.9%+1.1 pts
New / increased26 / 3245 / 36−28.4%
Reduced / sold out54 / 2336 / 30+16.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LXRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LXRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$2.8M6 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $2.7M between Feb 2 and Feb 25.
2026-02 bought $2.7M2026-11 bought $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 6Michael ExtonCEOBuy30,064$1.66$50K
Feb 25Raymond DebbaneDirectorBuy2,000$1.49$3K
Feb 23Raymond DebbaneDirectorBuy100,000$1.47$147K
Feb 20Raymond DebbaneDirectorBuy150,000$1.47$220K
Feb 18Raymond DebbaneDirectorBuy268,497$1.31$353K
Feb 2Artal Group S.A.DirectorBuy1,538,462$1.30$2.0M
Every insider buy and sale for LXRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LXRX insider trades →

From SEC Form 4 filings by LXRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXRX is in one of them and how their past LXRX trades turned out.

LXRX in the AI portfolios
Loading…

LXRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LXRX in an article yet. Here's the latest on the wider market.

LXRX in the news

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. It markets INPEFA, a tablet taken once a day that is approved in the United States to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure or related risk factors. Its drug candidates target hypertrophic cardiomyopathy, type 1 diabetes, and neuropathic pain, and it has licensed an obesity candidate to Novo Nordisk. INPEFA reaches patients through wholesalers, retail pharmacies, hospitals, and a mail order pharmacy, serving prescribers and patients.

Headquarters
The Woodlands, TX
Founded
1995